A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Part of paid clinical trials in Stanford, California.

Sponsor
George Albert Fisher
Study ID
NCT01108458
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pertuzumab — DRUG
    iv, 840 mg, 420 mg
  • Erlotinib — DRUG
    PO, 150 mg

Study Details

A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma

Key Dates

First listed
Apr 22, 2010
Start date
Jul 31, 2010
Status verified
Jan 2017
Primary completion
Nov 30, 2010
Completion
Mar 31, 2011

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pertuzumab plus Erlotinib Hydrochloride
    Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks Erlotinib hydrochloride 150 mg/day by mouth

Primary Outcome Measure

Overall Response Rate by RECIST Criteria [ Time Frame: CT imaging every 9 weeks while on protocol ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Stanford University School of Medicine· Stanford, CA

Related Studies